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A mouse renin-1 gene promoter f agment, normally inactive in B-cells, becomes a potent promoter in these 
cells after insertion of the highly conserved decanucleotide (dc/cd sequence) of immunoglobulin heavy and 
light chain promoters [(1987) EMBO J. 6, 1685--1690]. We observe retarded complexes of the same electro- 
phoretic mobility when the cd-containing renin promoter f agment or an authentic mmunoglobulin heavy 
chain promoter f agment is incubated with a nuclear extract from myeloma cells, suggesting that the renin 
promoter is activated ue to its acquired ability to bind a B-cell-specific positive factor. No retarded com- 
plexes are observed with the original renin promoter f agment thus questioning the presence of a repressor 
as an explanation for its lack of activity in B-cells. 
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1. INTRODUCTION 
The highly conserved sequence ATGCAAAT- 
NA (cd) is present upstream of the im- 
munoglobulin heavy chain genes and, in the 
opposite orientation (dc), in the corresponding 
region of the immunoglobulin light chain genes 
and in the immunoglobulin heavy chain enhancer 
element [1,2]. Binding of nuclear factors to the 
above regulatory elements has been reported 
[3-6]. Some of these factors are specific to ceils of 
the B lineage while others are ubiquitous [5,6]. 
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As shown in our laboratory, insertion of the cd 
sequence into the 5'-flanking region of a gene not 
normally transcribed in myeloma cell lines, in oc- 
currence the mouse renin gene, was sufficient o 
confer a strong transcriptional ctivity to this pro- 
moter in B-cells but not in non-lymphoid cells [7]. 
Here, we compare the binding of nuclear factors to 
the cd-containing renin promoter (Ren-cd), the in- 
tact renin promoter (Ren) and an authentic im- 
munoglobulin heavy chain promoter (Vn 
promoter). Using an electrophoretic mobility shift 
assay we show that the engineered renin promoter 
and the Vri promoter behave in an identical man- 
ner in the presence of a B-cell nuclear extract or of 
an extract of non-lymphoid origin. However, no 
binding is observed with the intact renin promoter. 
Abbreviations: dc/cd, decanucleotide element; Ig, im- 
munoglobulin; poly(dI-dC), poly(deoxyinosine-deoxy- 
cytosine); Ren, renin; V. promoter, immunoglobulin 
heavy chain promoter 
2. MATERIALS AND METHODS 
2. I. DNA probes 
Isolation of a Vn promoter fragment (V1) and of 
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the renin promoter fragment ( -142 to + 30 with 
respect o the main transcription startpoint) has 
been described [7,8]. Insertion of the 
decanucleotide (cd sequence) into the renin pro- 
moter fragment is also described in [7]. The 
fragments were end-labelled with [a-32p]deox - 
ynucleotides using the large fragment of E. coli 
DNA polymerase. 
2~ 
2.2. Cell culture and nuclear extract preparation 
Myeloma cells X63Ag8 secreting Ig were grown 
in suspension in Dulbecco's modified Eagle 
medium containing 10070 fetal calf serum. Nuclear 
extracts were prepared according to Dignam et al. 
[9]. The HeLa cell nuclear extract was a generous 
gift from Dr C. Kedinger. 
2.3. Electrophoretic mobility shift assay 
The 32p-labelled fragments (0.1-0.5 ng, 
10000 cpm) were incubated for 30 min at room 
temperature with 8/zg nuclear extract protein in a 
reaction mixture that contained 10 mM Tris-HC1 
(pH 7.5), 50 mM NaCl, 1 mM EDTA, 1 mM 
dithiothreitol, 7.5/zg poly(dI-dC) and 5°70 glycerol. 
At the end of the incubation period, glycerol was 
added to a final concentration of 10°70 and the 
samples were immediately loaded onto a 4.5°7o 
polyacrylamide gel (acrylamide/bisacrylamide, 
39: 1, w/w) containing 0.1 M Tris (pH 8.3), 0.1 M 
boric acid and 2 mM EDTA. The gel had been pre- 
electrophoresed for at least 30 min at 11 V-cm -1. 
The samples were electrophoresed for 10 min at 
15 V.cm -1 and then for 2 h at l l  V.cm -1. The 
gels were fixed, dried and autoradiographed at 
70°C with an intensifying screen. 
3. RESULTS AND DISCUSSION 
X63Ag8 is a myeloma cell line that secretes IgG 
1 [10]. Nuclear extracts prepared from these cells 
were incubated with the different radiolabelled 
fragments followed by polyacrylamide gel elec- 
trophoresis. Bands of reduced mobility were ob- 
tained with the immunoglobulin heavy chain 
promoter fragment (VI) and with the cd- 
containing renin promoter fragment (Ren-cd) but 
not with the original renin promoter (fig.l). The 
V1 and Ren-cd fragments displayed an identical 
pattern of bands, a pattern that resembles that 
described in other laboratories for the binding of 
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Fig.l. Electrophoretic mobility shift assay comparing 
the binding of factors to the V1, Ren-cd and Ren 
fragments. ( - )  No extract; X63Ag8, myeloma cell 
extract. Assay conditions are described in section 2. 
nuclear extracts of lymphoid origin with im- 
munoglobulin heavy or ~c light chain promoter 
fragments [5,6]. Two major bands are observed 
(nos 1,2 in fig.l) as well as other minor bands. In- 
cubation of the V1 or Ren-cd fragments with an 
extract from HeLa cells gave only one major band 
with a mobility similar to or slightly lower than 
that of band 1 observed with the X63Ag8 extract. 
Again no specific retardation of the original renin 
promoter fragment was observed. It is therefore 
possible that band 2 observed with the X63Ag8 ex- 
tract corresponds to the B-cell-specific omplex 
described in [6] whereas band 1 corresponds to a 
complex caused by an ubiquitous protein [5,6]. 
The bands of retarded mobility obtained with 
the V1 and Ren-cd fragments could be competed 
away by addition of excess unlabelled fragment to 
the incubation mixture (not shown). Moreover, the 
bands obtained with the VI fragment were com- 
peted away by addition of excess unlabelled Ren- 
cd fragment, hose obtained with the Ren-cd frag- 
ment being competed by the V1 fragment (fig.2). 
A synthetic oligonucleotide (20-mer) containing 
the cd sequence was an efficient competitor of the 
V I and Ren-cd fragments and formed complexes 
of retarded electrophoretic mobility when in- 
cubated with the X63Ag8 extract. 
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Fig.2. Binding competition analysis. (A) The Vl 
fragment (0.5 ng) was incubated with the X63Ag8 
extract as before in the absence or presence of unlabelled 
Ren-cd fragment. Lanes: (1) no extract; (2-5) 0, 1, 2.5, 
5 ng Ren-cd, respectively. (B) The Ren-cd fragment 
(0.5 ng) was incubated with the X63Ag8 extract in the 
absence or presence of V1. Lanes: (6) no extract; (7-10) 
0, l, 2.5, 5 ng Vl, respectively. 
The above observations strongly suggest that the 
presence of the decanucleotide s quence is suffi- 
cient to produce all the retarded complexes in the 
electrophoretic mobility shift assay. This is concor- 
dant with the recent observation by Landolfi and 
co-workers [11] that the retarded complexes ob- 
tained by incubation of lymphoid cell extract with 
a Vn promoter fragment are all due to binding of 
the factors with the nucleotides of the dc/cd se- 
quence. Moreover, computer comparison of the 
sequence of V1 and Ren-cd fragments hows that 
the only region of strong homology between the 
two is the cd sequence (not shown). 
The fragment of the renin promoter that was 
used in this work shows little promoter activity in 
lymphoid cells even when coupled to a functional 
enhancer. However, after insertion of the cd se- 
quence, this fragment becomes a potent promoter 
in B-cells provided it is associated with a functional 
enhancer [7]. We can suggest from the experiments 
presented here that the engineered renin fragment 
becomes an active promoter in B-cells because the 
insertion of the cd sequence has given it the capaci- 
ty to bind to a factor that is essential for promoter 
activity in these cells. This factor could be the one 
that produces complex 2 of fig. 1, i.e. the B-specific 
factor. An alternative interpretation would be that 
insertion of the cd sequence activates the renin pro- 
moter by disruption of a repressor-binding site. 
However, such binding could not be shown with 
the original renin promoter fragment with either 
the myeloma cell extract or the HeLa extract (fig. 1) 
even when the amounts of non-specific ompetitor 
DNA (poly(dI-dC)) used in the assay were reduced 
(not shown). 
Although the cd sequence has been shown to be 
important for the activity of several promoters in 
non-B-cells [12-16], introduction of the cd se- 
quence did not confer a strong promoter activity to 
the renin fragment when assayed in a mouse 
fibroblastic ell line [7]. Formation of the retarded 
complex produced by the ubiquitous factor that 
binds the cd sequence (band 1 in fig.1 and see 
[5,6,11]) may not be sufficient for a strong pro- 
moter activity in fibroblasts. It is therefore possi- 
ble that in the cases where binding of the 
ubiquitous factor to the cd sequence is important 
for promoter activity in non-B-cells, other se- 
quences and/or factors might be implicated as 
well. 
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